We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Sofinnova

News List

Sofinnova sells Breath Therapeutics to Zambon in $550m deal pharmaceutical-technology
July 29, 2019
Venture capital firm Sofinnova Partners has dispossessed its portfolio company Breath Therapeutics to Italian pharmaceutical firm Zambon for a total consideration of up to $550m (€500m), including a €140m upfront payment.
Zambon Acquires Sofinnova Partners’ Breath Therapeutics contractpharma
July 26, 2019
Italian pharma company purchases Breath Therapeutics for €500 million, with €140 million up front.
Sofinnova, LSP lead $17M round for gene therapy player XyloCor fiercebiotech
December 29, 2018
XyloCor Therapeutics raised $17 million in its series A round to advance a gene therapy pipeline for cardiovascular disease. Its lead asset is a treatment for angina that is poised to enter the clinic in 2019....